Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of
NET
NETest
PPQ
PRRT
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
02
05
2022
revised:
01
11
2022
medline:
5
4
2023
pubmed:
18
11
2022
entrez:
17
11
2022
Statut:
ppublish
Résumé
Reliable biomarkers for neuroendocrine tumor (NET) management during peptide receptor radionuclide therapy (PRRT) are lacking. We validated the role of 2 circulating biomarkers: the PRRT prediction quotient (PPQ) as a predictive marker for response and the NETest as a monitoring biomarker. Furthermore, we evaluated whether tissue-based genetic alterations are effective in predicting progression-free survival (PFS).
Identifiants
pubmed: 36396457
pii: jnumed.122.264363
doi: 10.2967/jnumed.122.264363
pmc: PMC10071782
doi:
Substances chimiques
copper dotatate CU-64
0
Somatostatin
51110-01-1
Octreotide
RWM8CCW8GP
Organometallic Compounds
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
567-573Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : K12 CA184746
Pays : United States
Informations de copyright
© 2023 by the Society of Nuclear Medicine and Molecular Imaging.
Références
J Clin Oncol. 2008 May 1;26(13):2124-30
pubmed: 18445841
Clin Cancer Res. 2012 Sep 15;18(18):5134-43
pubmed: 22832933
Lancet Oncol. 2020 Sep;21(9):e431-e443
pubmed: 32888472
PLoS One. 2013 May 15;8(5):e63364
pubmed: 23691035
J Clin Oncol. 2007 May 1;25(13):1753-9
pubmed: 17470865
Endocr Relat Cancer. 2017 May;24(5):243-251
pubmed: 28320783
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):331-332
pubmed: 28293026
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1155-1169
pubmed: 29484451
N Engl J Med. 2017 Jan 12;376(2):125-135
pubmed: 28076709
Clin Cancer Res. 2018 May 1;24(9):2182-2193
pubmed: 29440175
Neuroendocrinology. 2015;101(1):1-17
pubmed: 25228173
Clin Cancer Res. 2019 Dec 1;25(23):6939-6947
pubmed: 31439583
Eur J Nucl Med Mol Imaging. 2016 May;43(5):839-851
pubmed: 26596723
Eur J Nucl Med Mol Imaging. 2020 Apr;47(4):895-906
pubmed: 31838581
Endocr Relat Cancer. 2021 Oct 13;28(11):731-744
pubmed: 34515661
Nature. 2017 Mar 2;543(7643):65-71
pubmed: 28199314
BMC Genomics. 2012 Jul 30;13:348
pubmed: 22846430
BMC Med Genomics. 2017 May 19;10(1):33
pubmed: 28526081
J Nucl Med. 2021 Oct;62(10):1406-1414
pubmed: 33579805
Ann Oncol. 2020 Feb;31(2):202-212
pubmed: 31959337
BMC Cancer. 2021 Jan 28;21(1):101
pubmed: 33509126
Endocr Relat Cancer. 2015 Aug;22(4):561-75
pubmed: 26037279
Diagnostics (Basel). 2020 Dec 12;10(12):
pubmed: 33322819
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):489-96
pubmed: 19735873
Endocr Relat Cancer. 2010 Jan 29;17(1):R53-73
pubmed: 19995807
Virchows Arch. 2018 Dec;473(6):709-717
pubmed: 30219970
Rev Endocr Metab Disord. 2021 Sep;22(3):563-579
pubmed: 32978685
Oncotarget. 2018 Feb 15;9(24):16932-16950
pubmed: 29682195
J Mol Diagn. 2015 May;17(3):251-64
pubmed: 25801821
Oncologist. 2019 Jun;24(6):783-790
pubmed: 30158287